Search by Drug Name or NDC
NDC 00078-0904-98 SIMBRINZA 2; 10 mg/mL; mg/mL Details
SIMBRINZA 2; 10 mg/mL; mg/mL
SIMBRINZA is a OPHTHALMIC SUSPENSION/ DROPS in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is BRIMONIDINE TARTRATE; BRINZOLAMIDE.
MedlinePlus Drug Summary
Ophthalmic brimonidine is used to lower pressure in the eyes in patients who have glaucoma (high pressure in the eyes that may damage nerves and cause vision loss) and ocular hypertension (pressure in the eyes that is higher than normal but not high enough to cause vision loss). Brimonidine is in a class of drugs called alpha adrenergic agonists. Brimonidine works by decreasing the amount of fluid in the eyes.
Related Packages: 00078-0904-98Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Brimonidine Ophthalmic
Ophthalmic Brinzolamide is used to treat glaucoma, a condition that increases pressure in the eye and leads to vision loss. Brinzolamide is in a class of medications called carbonic anhydrase inhibitors. It decreases the pressure in the eye.
Related Packages: 00078-0904-98Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Brinzolamide Ophthalmic
Product Information
| NDC | 00078-0904 |
|---|---|
| Product ID | 0078-0904_c2a9e73d-9414-489a-9840-aa8aae4cdd00 |
| Associated GPIs | 86609902201820 |
| GCN Sequence Number | 070913 |
| GCN Sequence Number Description | brinzolamide/brimonidine tart DROPS SUSP 1 %-0.2 % OPHTHALMIC |
| HIC3 | Q6G |
| HIC3 Description | MIOTICS AND OTHER INTRAOCULAR PRESSURE REDUCERS |
| GCN | 34579 |
| HICL Sequence Number | 040260 |
| HICL Sequence Number Description | BRINZOLAMIDE/BRIMONIDINE TARTRATE |
| Brand/Generic | Brand |
| Proprietary Name | SIMBRINZA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | brinzolamide/brimonidine tartrate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SUSPENSION/ DROPS |
| Route | OPHTHALMIC |
| Active Ingredient Strength | 2; 10 |
| Active Ingredient Units | mg/mL; mg/mL |
| Substance Name | BRIMONIDINE TARTRATE; BRINZOLAMIDE |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Pharmaceutical Class | Adrenergic alpha-Agonists [MoA], Carbonic Anhydrase Inhibitor [EPC], Carbonic Anhydrase Inhibitors [MoA], alpha-Adrenergic Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA204251 |
| Listing Certified Through | n/a |
Package
NDC 00078-0904-98 (00078090498)
| NDC Package Code | 0078-0904-98 |
|---|---|
| Billing NDC | 00078090498 |
| Package | 1 BOTTLE in 1 CARTON (0078-0904-98) / 2.5 mL in 1 BOTTLE |
| Marketing Start Date | 2020-08-04 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |